Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Introduction
- Advantages of Protein PEGylation
- Limitations of PEGylated Therapeutics
Chapter 3 Market Dynamics
- Market Dynamics Snapshot
- Market Drivers
- Protein Drugs in Hematology and Oncology
- Design of Biobetters
- Market Restraints
- Immunogenicity and Side Effects
- Formulation Challenges
- Market Opportunities
- Site-Specific PEGylation
- New Indications and Formulation Techniques
Chapter 4 Emerging Technologies and Developments
- Introduction
- Non-Covalent PEGylation
- PEGylation of Nanoparticles
- Antibody-Drug Conjugates (ADCs)
Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Global PEGylated Proteins Market, by Protein Type
- Granulocyte-Colony Stimulating Factors (G-CSF)
- PEGylated Monoclonal Antibodies
- PEGylated Interferons
- PEGylated Recombinant Factors
- Other Protein Types
- Global PEGylated Proteins Market, by PEGylation Type
- Linear PEGylated Proteins
- Branched PEGylated Proteins
- Global PEGylated Proteins Market, by PEGylation Application
- Autoimmune Diseases
- Hematology
- Cancer
- Other Applications
- Geographic Breakdown
- Global Market for PEGylated Proteins, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Competitive Intelligence
- Recent Developments in the PEGylated Proteins Market
- Clinical Trial Activities
Chapter 7 Sustainability in the PEGylated Proteins Market: ESG Perspective
- Introduction
- Sustainability in the PEGylated Proteins Industry
- Understanding the ESG Data
- Environmental Performance
- Social Performance
- Governance Performance
- Concluding Remarks
List of Tables
Summary Table: Global Market for PEGylated Proteins, by Region, Through 2028
Table 1: PEGylated Drugs in Clinical Trials for Cancer
Table 2: Discontinued PEGylated Drugs in Clinical Trials
Table 3: Side Effects Observed with Approved Products
Table 4: Global Market for PEGylated Proteins, by Protein Type, Through 2028
Table 5: Marketed PEGylated G-CSF Drugs
Table 6: Global Market for G-CSF, by Region, Through 2028
Table 7: Global Market for PEGylated mAbs, by Region, Through 2028
Table 8: Global Market for PEGylated Interferons, by Region, Through 2028
Table 9: Global Market for PEGylated Recombinant Factors, by Region, Through 2028
Table 10: Global Market for Other Protein Types, by Region, Through 2028
Table 11: Global Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 12: Global Market for Linear PEGylated Proteins, by Region, Through 2028
Table 13: Global Market for Branched PEGylated Proteins, by Region, Through 2028
Table 14: Global Market for PEGylated Proteins, by Application, Through 2028
Table 15: Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, Through 2028
Table 16: Global Market for PEGylated Proteins for Hematology, by Region, Through 2028
Table 17: Global Market for PEGylated Proteins for Cancer, by Region, Through 2028
Table 18: Global Market for PEGylated Proteins for Other Applications, by Region, Through 2028
Table 19: Global Market for PEGylated Proteins, by Region, Through 2028
Table 20: North American Market for PEGylated Proteins, by Country, Through 2028
Table 21: North American Market for PEGylated Proteins, by Protein Type, Through 2028
Table 22: North American Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 23: North American Market for PEGylated Proteins, by Application, Through 2028
Table 24: European Market for PEGylated Proteins, by Country, Through 2028
Table 25: European Market for PEGylated Proteins, by Protein Type, Through 2028
Table 26: European Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 27: European Market for PEGylated Proteins, by Application, Through 2028
Table 28: Asia-Pacific Market for PEGylated Proteins, by Country, Through 2028
Table 29: Asia-Pacific Market for PEGylated Proteins, by Protein Type, Through 2028
Table 30: Asia-Pacific Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 31: Asia-Pacific Market for PEGylated Proteins, by Application, Through 2028
Table 32: RoW Market for PEGylated Proteins, by Protein Type, Through 2028
Table 33: RoW Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 34: RoW Market for PEGylated Proteins, by Application, Through 2028
Table 35: Recent Developments in PEGylated Proteins Market, 2022 and 2023
Table 36: Competitor Clinical Trial Activities in PEGylated Protein Therapeutics, by Phase, 2023
Table 37: ESG Risk Rankings for Major PEGylated Protein Drug Companies*
Table 38: ESG: Environmental Overview
Table 39: ESG: Social Overview
Table 40: ESG: Governance Overview
Table 41: Report Sources
Table 42: Abbreviations Used in this Report
Table 43: Amgen Inc.: Company Snapshot
Table 44: Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 45: Amgen Inc.: Product Portfolio
Table 46: Amgen Inc.: News/Key Developments, 2023
Table 47: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 48: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 49: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 50: Merck KGaA: Company Snapshot
Table 51: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 52: Merck KGaA: Product Portfolio
Table 53: Merck KGaA: News/Key Developments, 2022 and 2023
Table 54: Pfizer Inc.: Company Snapshot
Table 55: Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 56: Pfizer Inc.: Product Portfolio
Table 57: Pfizer Inc.: News/Key Developments, 2023
Table 58: Sandoz Group AG: Company Snapshot
Table 59: Sandoz Group AG: Financial Performance, FY 2022 and 2023
Table 60: Sandoz Group AG: Product Portfolio
Table 61: Sandoz Group AG: News/Key Developments, 2023
List of Figures
Summary Figure: Global Market for PEGylated Proteins, by Region, 2020-2028
Figure 1: Advantages of Protein PEGylation
Figure 2: Timeline of PEGylated Protein Therapeutics
Figure 3: Disadvantages of PEGylated Protein Therapeutics
Figure 4: Market Dynamics of Global PEGylated Proteins
Figure 5: Emerging Technologies in the PEGylated Proteins Market
Figure 6: Global Market Shares of PEGylated Proteins, by Protein Type, 2022
Figure 7: Global Market for G-CSF, by Region, 2020-2028
Figure 8: Global Market for PEGylated mAbs, by Region, 2020-2028
Figure 9: Global Market for PEGylated Interferons, by Region, 2020-2028
Figure 10: Global Market for PEGylated Recombinant Factors, by Region, 2020-2028
Figure 11: Global Market for Other Protein Types, by Region, 2020-2028
Figure 12: Global Market Shares of PEGylated Proteins, by PEGylation Type, 2022
Figure 13: Global Market for Linear PEGylated Proteins, 2020-2028
Figure 14: Global Market for Linear PEGylated Proteins, by Region, 2020-2028
Figure 15: Global Market for Branched PEGylated Proteins, 2020-2028
Figure 16: Global Market for Branched PEGylated Proteins, by Region, 2020-2028
Figure 17: Global Market Shares of PEGylated Proteins, by Application, 2022
Figure 18: Global Market for PEGylated Proteins for Autoimmune Diseases, 2020-2028
Figure 19: Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, 2020-2028
Figure 20: Global Market for PEGylated Proteins for Hematology, 2020-2028
Figure 21: Global Market for PEGylated Proteins for Hematology, by Region, 2020-2028
Figure 22: Global Market for PEGylated Proteins for Cancer, 2020-2028
Figure 23: Global Market for PEGylated Proteins for Cancer, by Region, 2020-2028
Figure 24: Global Market for PEGylated Proteins for Other Applications, 2020-2028
Figure 25: Global Market for PEGylated Proteins for Other Applications, by Region, 2020-2028
Figure 26: Global Market Shares of PEGylated Proteins, by Region, 2022
Figure 27: Global Market for PEGylated Proteins, by Region, 2020-2028
Figure 28: North American Market Shares of PEGylated Proteins, by Country, 2022
Figure 29: European Market Shares of PEGylated Proteins, by Country, 2022
Figure 30: Asia-Pacific Market Shares of PEGylated Proteins, by Country, 2022
Figure 31: Snapshot of ESG Pillars
Figure 32: Advantages of ESG for Companies
Figure 33: Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 34: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 35: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 36: Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 37: Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 38: Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 39: Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 40: Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
Figure 41: Sandoz Group AG: Revenue Share, by Country/Region, FY 2023
